Prolight is well-positioned to deliver POC platforms to satisfy a number of clinical unmet needs. The platform is initially being developed for areas with significant unmet medical needs, such as cardiovascular and neurological conditions, but has the potential to be used across a broad range of clinical applications.
Through the acquisition of Psyros, Prolight now has an entirely novel cutting-edge POC technology for digital immunoassay, which can count individual molecules from a single drop of blood. The unique technology opens up the possibility of developing new POC tests in a wide range of clinical areas that were previously only possible in specialised laboratories. Further advantages of the digital immunoassay include its simplicity and low production costs.
Picture taken at Psyros lab.
Today, PCR tests are recommended to confirm Covid, but the response time is lengthy, sometimes several hours to days, depending on the system. By using our digital assay technology, it is possible to count individual molecules at low levels, including viral particle proteins, such as coronavirus. As a result, sensitivity and accuracy can be as good or better than PCR tests currently offered on large central laboratory instruments. The large and highly significant difference between today’s PCR tests and Prolight’s innovative digital POC platform is that the response time can be reduced to just ten minutes or less.
This novel technology could mark the beginning of a paradigm shift in POC testing for clinical diagnostics. The unique technology behind the digital immunoassay will make it possible to test a range of biomarkers with high sensitivity and accuracy on a single POC instrument. Prolight believes that this technology could be the future of POC testing.
Some examples of possible future clinical areas are: